Kamal Choudhury

1 week ago | today.westlaw.com | Patrick Wingrove |Mohammed Shamsi |Savyata Mishra |Kamal Choudhury

(Reuters) -U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies regulated by the agency, such as pharmaceutical firms, from serving as official members on FDA's advisory...

1 month ago | sightmagazine.com.au | Mariam Sunny |Kamal Choudhury |David Adams

ReutersTuberculosis (TB) infections among children in the European region rose 10 per cent in 2023, indicating ongoing transmission and the need for immediate public health measures to control the spread, the World Health Organization said on Monday. WHO’s European region, which comprises 53 countries in Europe and Central Asia, reported more than 7,500 cases among children under 15 years of age in 2023, an increase of over 650 cases compared to 2022.

1 month ago | risingnepaldaily.com | Mariam E Sunny |Kamal Choudhury

By Mariam E Sunny and Kamal Choudhury, March 24: Tuberculosis (TB) infections among children in the European region rose 10% in 2023, indicating ongoing transmission and the need for immediate public health measures to control the spread, the World Health Organization said on Monday. WHO's European region, which comprises 53 countries in Europe and Central Asia, reported more than 7,500 cases among children under 15 years of age in 2023, an increase of over 650 cases compared to 2022.

1 month ago | conexiant.com | Kamal Choudhury |Siddhi Mahatole

Incyte's oral JAK1 inhibitor, povorcitinib, met the primary endpoint in two separate phase 3 trials for hidradenitis suppurativa, the company announced. However, efficacy outcomes were lower than those observed in prior studies. In one of the trials, 40.2% of patients receiving povorcitinib achieved a reduction in abscess and inflammatory nodule count at 12 weeks, compared to 29.7% in the placebo group.

2 months ago | azdailysun.com | Sriparna Roy |Kamal Choudhury

By Sriparna Roy and Kamal Choudhury(Reuters) - The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first treatment for a rare condition that interferes with the body's ability to process cholesterol. Patients with the disorder known as cerebrotendinous xanthomatosis are unable to break down cholesterol properly, causing toxins to build up throughout the body over time.